NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

A single center, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.

Trial Details

NCT ID

NCT06889766

Phase

PHASE1

Sponsor

Centre Hospitalier Universitaire Vaudois

Status

RECRUITING

Cancer Type

Melanoma

Interventions

NY-ESO-1 TCR redirected autologous T cell product
Low-dose irradiation
Non-myeloablative lymphodepleting chemotherapy

Locations (sample)

Lausanne, Canton of Vaud, Switzerland|46.516,6.63282
Lausanne, Canton of Vaud, Switzerland|46.516,6.63282

Key Eligibility Criteria

Inclusion criteria at pre-screening step-2
1\) Immunohistochemically documented NY-ESO-1 expression, defined as ≥ 1+ expression on either archival or fresh tumor tissue by immunohistochemist…
Inclusion criteria at screening
Patients with sarcoma, who have received at least one line of standard therapy (if available) and failed to respond, progressed or were intolerant …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →